BioTech
Biotechnology companies operate in one of the most complex environments in business – and the right financial, tax, and operational support can make the difference between scaling and stalling.
Your biotech company is racing toward clinical milestones that could transform patient care. Every dollar matters when you’re years away from revenue, managing multiple research programs, and preparing for your next funding round. Yet you’re wrestling with critical financial questions:
- R&D capitalization: Determining which development costs to capitalize as your programs advance through clinical stages
- Tax credit documentation: Capturing qualified research expenses across diverse research activities and demonstrating nexus for state credits
- Investor reporting: Explaining burn rate and runway to investors who want to see both scientific progress and financial discipline
- Revenue Recognition: Once FDA approval is received, and your product has launched, the vast complexity of revenue recognition now creates new challenges, primarily in relation to how to appley Gross-vs-Net (GTN) accounting.
The accounting and tax complexity unique to biotech threatens to pull focus from the innovation that defines your mission. This challenge intensifies as you advance through development stages, where a promising Phase II result can accelerate your timeline and capital needs overnight, where partnership negotiations require sophisticated tax structuring, and where every financial decision from equity compensation to international expansion carries implications that ripple through multiple fiscal years. Your financial infrastructure needs to support rapid pivots while maintaining the documentation rigor that investors, auditors, and eventually regulators will scrutinize.
Connect with a Life Sciences Professional
The Unique Financial Landscape of Biotechnology
Biotech companies operate in a financial environment unlike any other sector:
Burning cash for five to ten years before potential commercialization while managing research portfolios where a single asset might consume tens of millions before reaching proof of concept
Navigating a capital landscape where your next raise depends on scientific milestones that may or may not hit projected timelines
Maintaining the financial visibility that institutional investors expect through accurate, timely reporting
Applying gross-to-net accounting for product revenue, from estimating rebates, chargebacks, and discounts to building the documentation that supports your assumptions through an audit
Making daily decisions about resource allocation across programs, each with different risk profiles and capital requirements
Building the compliance posture that positions your company for future success
Our Biotech Financial Services
BPM works exclusively with companies that understand the scientific, regulatory, and financial complexity of bringing novel therapeutics to market. Our integrated approach addresses the interconnected challenges biotech companies face as they advance from discovery through clinical development and toward commercialization.
Research & Development Tax Credits
Biotech companies generate substantial R&D tax credits, but capturing their full value requires meticulous documentation of qualified research expenses across multiple programs, contract research relationships, and development activities. We help you establish documentation processes that capture credits in real time rather than reconstructing them later, structure CRO relationships to optimize credit eligibility, and defend your positions when tax authorities question biotechnology research qualification.
International Tax & Transfer Pricing
As you expand research activities internationally, establish foreign subsidiaries, or enter licensing arrangements with global partners, transfer pricing and international tax structuring become critical. We help you establish intercompany agreements that allocate value appropriately while withstanding tax authority scrutiny, structure international collaborations to minimize withholding tax friction, and develop transfer pricing documentation that supports your positions across jurisdictions.
IPO Readiness & Transaction Support
Whether you're preparing for public markets or positioning for acquisition, the financial scrutiny intensifies dramatically. We provide the technical accounting support, audit readiness preparation, and internal controls implementation that satisfy public company requirements or strategic buyer expectations.
Clinical Stage Financial Management
Moving into clinical trials transforms your financial operations, with CRO payments, site management costs, and patient enrollment expenses that fluctuate unpredictably and must be tracked across multiple studies and geographies. Our accounting teams help you implement accrual methodologies for clinical expenses that satisfy auditors and provide reliable forecasts, develop reporting that gives your board visibility into program-level economics, and prepare the financial infrastructure you'll need for partnership discussions or liquidity events.
Deep Biotech Sector Knowledge
We understand the scientific and business terminology that defines your industry. Our professionals know how to evaluate the financial implications of orphan drug designation, breakthrough therapy status, and adaptive trial designs. We’ve worked with companies developing cell and gene therapies, monoclonal antibodies, small molecules, and novel modalities. This familiarity means we’re having substantive conversations about your business rather than requiring education about basic biotech economics.
Start the conversation
Looking for a team who understands where you’re headed and how to help you get there? Whether you’re building something new, managing growth or preserving success, let’s talk.